IL-5 prolongs allograft survival by downregulating IL-2 and IFN-gamma cytokines.
Department of Medicine, Liverpool Hospital and University of New South Wales, NSW, Liverpool, Australia.
X Y
XY
He
N
N
Verma
J
J
Chen
C
C
Robinson
R
R
Boyd
B M
BM
Hall
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016466:CHO Cells; D006224:Cricetinae; D015536:Down-Regulation; D006085:Graft Survival / Q000187:drug effects* / Q000502:physiology; D016027:Heart Transplantation / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism*; D007376:Interleukin-2 / Q000378:metabolism*; D015847:Interleukin-4 / Q000378:metabolism / Q000494:pharmacology; D015848:Interleukin-5 / Q000494:pharmacology*; D051381:Rats; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism; D013997:Time Factors; D023001:Transplantation Tolerance / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D015848:Interleukin-5; D015847:Interleukin-4; D007371:Interferon-gamma